Table 1.

Participant demographic and implant information.

Patient	Diagnosis	Sex	Age (years)	Months post DBS implantation	Years since onset of symptoms	Model/device	Unilateral/bilateral	Clinically set pulse duration (μs)	Clinically set frequency (Hz)	Clinically set amplitude	Randomized amplitude settings by patientc
1	ET	M	72	4	18	St Judes Brio ActiveTip 3 mm leadsa	Bilateral	90	130	2.5 (bilateral)	0.0, 0.75, 1.5, 2.2, 3.0, 3.5, 4.0
2	ET	F	48	17	20	Medtronic activa RC model 3387b	Bilateral	90	130	2.5 (bilateral)	0.0, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5
3	Cerebellar intention tremor	F	71	15	35	St Jude Libra ActiveTip 3 mm leadsa	Bilateral	90	130	1.4 (L), 0.6 (R)	0.0, 0.6, 1.5, 2.1, 2.8, 3.5, 4.2
4	Dystonic tremor	F	47	6	25	Medtronic activa RC model 3387b	Bilateral	90	130	3.5 (L), 2.3 (R)	0.0, 1.5, 1.8, 2.1, 2.4, 2.7, 3.0
5	ET	M	56	16	18	Medtronic activa RC model 3387b	Bilateral	90	130	2.4 (L), 3.3 (R)	3.3, 3.8, 4.4, 5.0, 5.4, 5.8d
6	ET	F	44	15	30	Medtronic activa RC model 3387b	Bilateral	60	150	2.3 (bilateral)	0.0, 1.5, 1.9, 2.4, 3.0, 3.6, 4.3

^aDevice measured in milliamps.

^bDevice measured in volts.

^cPulse duration and frequency set to 90 and 130, respectively, for all patients and conditions.

^dParticipant became emotionally labile when lower voltages were attempted.

ET, essential tremor; L, left; R, right; Hz, Hertz; mA, milliamps; M, male; F, female.

Patient 6 treated with clonazepam 0.5 mg/day in addition to DBS. All patients implanted bilaterally.